Total-body PET and highly stable chelators together enable meaningful 89Zr-antibody-PET studies up to 30 days post-injection.
Rationale: The use of 89Zr-antibody-PET imaging to measure antibody biodistribution and tissue pharmacokinetics is well established, but current PET imaging systems lack the sensitivity needed to study 89Zr-labeled antibodies beyond two to three isotope half-lives (7-10 days), after which poor signal-to-noise is problematic. However, studies across many weeks are desirable to better match antibody circulation half-life in human and nonhuman primates. These studies investigated the technical feasibility of using the primate mini-EXPLORER PET scanner, making use of its high sensitivity and 45 cm axial field-of-view (FOV), for total-body imaging of 89Zr-labeled antibodies in rhesus monkeys up to 30-days post-injection. Methods: A humanized monoclonal IgG antibody against the herpes simplex viral protein gD was radiolabeled with 89Zr via one of four chelator-linker combinations (DFO-Bz-NCS, DFO-squaramide, DFO*-Bz-NCS, and DFO*-squaramide). The pharmacokinetics associated with these chelator-linker combinations were compared in 12 healthy young male rhesus monkeys (~1-2 years of age, ~3 ±1 kg). Each animal was initially injected intravenously with unlabeled antibody (10 mg/kg providing therapeutic-level antibody concentrations; right), which was then immediately followed by ~40 MBq of one of the 89Zr-labeled antibodies injected intravenously at a contralateral site (left). All animals were imaged six times over a period of 30 days, with an initial 60-minute dynamic scan on day 0 (day of injection), followed by static scans of 30-45 minutes on approximately days 3, 7, 14, 21, and 30, with all acquired using a single bed position and images reconstructed using a time-of-flight listmode OSEM algorithm. Activity concentrations in various organs were extracted from the PET images using manually defined regions-of-interest (ROIs). Results: Excellent image quality was obtained, capturing the initial distribution phase in the whole-body scan, later time points showed residual 89Zr mainly in the liver. Even at 30 days post-injection, representing approximately 9 half-lives of 89Zr and with a total residual activity in the animal of only 20-40 kBq, the image quality was sufficient to readily identify activity in the liver, kidneys, and bone joints. Significant differences were noted in late time-point liver uptake, bone uptake, and whole-body clearance between chelator-linker types, while little variation (±10%) was observed within each type. Conclusion: These studies demonstrate the ability to image 89Zr radiolabeled antibodies up to 30 days post-injection while maintaining satisfactory image quality provided by the primate mini-EXPLORER with high sensitivity and long axial FOV. Quantification demonstrated potentially important differences in the behavior of the four chelators, which supports further investigation.